[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
July 8, 2009

NIH Program to Boost Pipeline for Drugs to Treat Rare and Neglected Diseases

JAMA. 2009;302(2):133-134. doi:10.1001/jama.2009.940

The National Institutes of Health (NIH) is launching a program that will shepherd drug candidates aimed at treating rare and neglected diseases through the most challenging phase of drug development.

The program, called Therapeutics for Rare and Neglected Diseases (TRND), marks the agency's largest foray into developing drugs. It will bring together expertise from various sectors of the NIH—including the Office of Rare Diseases Research (ORDR), the National Human Genome Research Institute, and the NIH Chemical Genomics Center (NCGC)—as well as expertise from outside researchers and organizations. TRND's focus will be moving candidate molecules through the preclinical phase of development and then licensing the candidates to other entities for further development.

First Page Preview View Large
First page PDF preview
First page PDF preview
×